Anti-Agitation Drug Comes Up Short in Phase 3
Negative findings for AVP-786 belie positive findings from a separate Phase 3 trial announced earlier this year.
ALL NEWS
5781 RESULTS
Sort By:
- Most Recent
- Most Commented
Rare Luck: Two Copies of ApoE2 Shield Against Alzheimer’s
ApoE2 homozygotes have a dramatically lower risk of AD than even the previously known low-risk E2/3 heterozygotes. More study of this protective allele could reveal roots of resilience.
As DIAN Wraps Up Anti-Aβ Drug Arms, it Sprouts Tau, Primary Prevention Arms
The DIAN Trials Unit is nearing the end of its first two secondary prevention trials. It has begun a cognitive run-in period for its next trial, of a tau-based drug, and for a primary prevention study in people as young as 18.
Multimodal Imaging of Neurodegenerative Diseases Links Pathology and Cellular Dysfunction
Synapse loss and mitochondrial stress, as seen by separate PET tracers, go hand-in-hand in Alzheimer’s, Parkinson’s, and frontotemporal dementia.
Paper Alert: Phase 3 Trial Data Published on Sleep Aid Suvorexant
FDA approves adding safety and efficacy data from an Alzheimer’s trial to the drug’s label.
New Myelin Makes Memories, but Supply Wanes with Age
The creation of long-term memories requires a continual supply of myelin provided by newly formed oligodendrocytes. Alas, the generation of fresh oligodendrocytes diminishes with age, along with memory.
International Symposium Puts PSP/CBD on the Map
Researchers gain traction in the study of these rare tau disorders, which are sometimes confused with Alzheimer’s disease.
Retinal Gene Therapy Trial Posts Positive Result
Vision improved in some retinitis pigmentosa patients in a Phase 1 trial.
Fluid NfL Shines, Tau PET Dims, in the Hunt for FTD Biomarkers
Researchers at an international frontotemporal dementia congress reported progress in finding markers that track disease, but no luck thus far with diagnostic markers.
Tau-PET in Down’s: Unique Patterns Among Alzheimer’s Types and Stages
At CTAD, tau-PET data from people in different stages of various neurodegenerative diseases highlighted both commonalities and peculiarities.
Data from DIAN Revise Familiar Biomarker Trajectories
Rather than changing one by one, many biomarkers—including cognition, tau PET, hippocampal atrophy, and CSF p-tau—shift together, around the time of symptom onset in young adults with familial AD.
PET Tracer Detects Synapse Loss Across Alzheimer’s Brain
New research presented at the HAI conference also finds links between UCB-J uptake and plaques, tangles, and cognitive decline.
American Academy of Neurology 2019 Annual Meeting
Antisense Oligonucleotides: Can They Take on ALS, SMA, Prions? Drug Reported to Help Alzheimer’s Patients Sleep Better American Academy of Neurology 2019 Annual Meeting ...
Can PET Match Up Areas of Protein Deposit With Alzheimer’s Symptoms?
Amyloid and tau PET are helping scientists pinpoint the underlying cause of specific AD symptoms. Perhaps imaging of certain brain regions will help predict an individual’s progression.
How Much Amyloid Will Kick Off Tangles, and Decline?
At HAI 2020, scientists more precisely quantified the relationship between plaques, tangles, and cognitive decline.
Current Filters
- Date Range : All x